Silencing of HIF-1α enhances the radiation sensitivity of human glioma growth in vitro and in vivo

Neuropharmacology

Volumn 89, Issue , 2015, Pages 168-174

  Luo, Zhonghua ^a   Bai, Minghua ^b   Xiao, Xian ^a   Zhang, Wei ^a   Liu, Xuedong ^a   Yang, Xiaoliang ^c   Li, Sanzhong ^a   Huan, Yi ^a   Wu, Zhiqun ^a   Zhang, Xiang ^a   Cao, Weidong ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b XI'AN JIAOTONG UNIVERSITY   (China)

^c 3rd Hospital of People Liberation Army   (China)

Author keywords

Gliomas; HIF 1 ; Pathway; Radiation sensitivity; RNAi

Indexed keywords

CYCLIN B1; CYCLIN DEPENDENT KINASE 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN BCL 2; SMALL INTERFERING RNA; HIF1A PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOWN REGULATION; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; GENE SILENCING; GLIOMA; GLIOMA CELL LINE; HIF 1A GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR VOLUME; ANIMAL; BRAIN NEOPLASMS; DEFICIENCY; DRUG SCREENING; GENETICS; METABOLISM; NUDE MOUSE; PHYSIOLOGY; PROCEDURES; RADIATION DOSE; TUMOR CELL LINE;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE SILENCING; GLIOMA; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MICE, NUDE; RADIATION TOLERANCE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84908599547     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2014.05.009     Document Type: Article

References (37)

1. W.D. Cao, N. Kawai, K. Miyake, X. Zhang, and T. Tamiya Relationship of 14-3-3zeta (ζ), HIF-1α, and VEGF expression in human brain gliomas Brain Tumor Pathol. 2013 1 10.1007
2. J.S. Carew, J.A. Esquivel, C.M. Espitia, C.M. Schultes, and M. Mülbaier ELR510444 inhibits tumor growth and angiogenesis by abrogating HIF activity and disrupting microtubules in renal cell carcinoma PLoS One 7 2012 e31120
3. H.J. Cho, K.E. Baek, S.M. Park, I.K. Kim, and I.K. Nam RhoGDI2 confers gastric cancer cells resistance against cisplatin-induced apoptosis by upregulation of Bcl-2 expression Cancer Lett. 311 2011 48 56
4. E.U. Cidon, S.G. Ellis, Y. Inam, S. Adeleke, S. Zarif, and T. Geldart Molecular targeted agents for gastric cancer: a step forward towards personalized therapy Cancers 5 1 2013 64 91
5. C. Culver, A. Melvin, S. Mudie, and S. Rocha HIF-1αdepletion results in SP1- mediated cell cycle disruption and alters the cellular response to chemotherapeutic drugs Cell Cycle 10 2011 1249 1260
6. B.C. Dash, and W.S. El-Deiry Phosphorylation of p21 in G2/M promotes cyclin B-Cdc2 kinase activity Mol. Cell. Biol. 25 2005 3364 3387
7. N. Droin, C. Rébé, F. Bichat, A. Hammann, and R. Bertrand Modulation of apoptosis by procaspase-2 short isoform: selective inhibition of chromatin condensation, apoptotic body formation and phosphatidylserine externalization Oncogene 20 2011 260 269
8. J.V. Dungwa, L.P. Hunt, and P. Ramani Overexpression of carbonic anhydrase and HIF-1αin Wilms tumours BMC Cancer 11 2011 390
9. M.B. Elstrand, L. Kleinberg, E.C. Kohn, C.G. Tropé, and B. Davidson Expression and clinical role of antiapoptotic proteins of the bag, heat shock, and Bcl-2 families in effusions, primary tumors, and solid metastases in ovarian carcinoma Int. J. Gynecol. Pathol. 28 2009 211 221
10. B. Escudier, L. Albiges, and G. Sonpavde Optimal management of metastatic renal cell carcinoma: current status Drugs 73 5 2013 427 438
11. X. Gao, J.T. McDonald, L. Hlatky, and H. Enderling Acute and fractionated irradiation differentially modulate glioma stem cell division kinetics Cancer Res. 73 5 2013 1481 1490
12. D.L. Gillespie, J.R. Flynn, B.T. Ragel, M. Arce-Larreta, and D.A. Kelly Silencing of HIF-1alpha by RNA interference in human glioma cells in vitro and in vivo Methods Mol. Biol. 487 2009 283 301
13. A. Güttler, M. Giebler, P. Cuno, H. Wichmann, J. Keßler, C. Ostheimer, A. Söling, C. Strauss, J. Illert, M. Kappler, D. Vordermark, and M. Bache Osteopontin and splice variant expression level in human malignant glioma: radiobiologic effects and prognosis after radiotherapy Radiother. Oncol. 108 3 2013 535 540
14. D.W. Jun, Y.S. Jeong, H.J. Kim, K.C. Jeong, S. Kim, and C.H. Lee Characterization of DDRI-18 (3,3'-(1H,3'H-5,5'-bibenzo[d]imidazole-2,2'-diyl) dianiline), a novel small molecule inhibitor modulating the DNA damage response Br. J. Pharmacol. 167 2012 141 150
15. S. Kim, H.S. Lee, S.K. Lee, S.H. Kim, and S.M. Hur 12-O-Tetradecanoyl phorbol-13-acetate (TPA)-induced growth arrest is increased by silibinin by the down-regulation of cyclin B1 and cdc2 and the up-regulation of p21 expression in MDA-MB231 human breast cancer cells Phytomedicine 17 2010 1127 1132
16. D. Krex, B. Klink, C. Hartmann, T. Pietsch, and A. von Deimling Long-term survival with glioblastoma multiforme Brain 130 2007 2596 2606
17. H.Y. Liao, G.P. Wang, L.J. Gu, S.H. Huang, X.L. Chen, Y. Li, and S.W. Cai HIF-1α siRNA and cisplatin in combination suppress tumor growth in a nude mice model of esophageal squamous cell carcinoma Asian Pac. J. Cancer Prev. 13 2 2012 473 477
18. H.W. Lo Targeting Ras-RAF-ERK and its interactive pathways as a novel therapy for malignant gliomas Curr. Cancer Drug Targets 10 2010 840 848
19. T.W. Meijer, J.H. Kaanders, P.N. Span, and J. Bussink Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy Clin. Cancer Res. 18 2012 5585 5594
20. H. Menrad, C. Werno, T. Schmid, E. Copanaki, and T. Deller Roles of hypoxia- inducible factor-1alpha (HIF-1alpha) versus HIF-2alpha in the survival of hepatocellular tumor spheroids Hepatology 51 2010 2183 2192
21. P. Merle, B. Evrard, A. Petitjean, J.M. Lehn, and M.P. Teulade-Fichou Telomere targeting with a new G4 ligand enhances radiation-induced killing of human glioblastoma cells Mol. Cancer Ther. 10 2011 1784 1795
22. J.R. Molina, F.C. Morales, Y. Hayashi, K.D. Aldape, and M.M. Georgescu Loss of PTEN binding adapter protein NHERF1 from plasma membrane in glioblastoma contributes to PTEN inactivation Cancer Res. 70 2010 6697 6703
23. J.R. Molina, N.K. Agarwal, F.C. Morales, Y. Hayashi, and K.D. Aldape PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma Oncogene 31 2012 1264 1274
24. B. Nayak, V.K. Kondeti, P. Xie, S. Lin, and N. Viswakarma Transcriptional and post-translational modulation of myo-inositol oxygenase by high glucose and related pathobiological stresses J. Biol. Chem. 286 2011 27594 27611
25. J.H. Park, J.Y. Lee, D.H. Shin, K.S. Jang, and H.J. Kim Loss of Mel-18 induces tumor angiogenesis through enhancing the activity and expression of HIF-1α mediated by the PTEN/PI3K/Akt pathway Oncogene 30 2011 4578 4589
26. P. Sapra, P. Kraft, F. Pastorino, D. Ribatti, and M. Dumble Potent and sustained inhibition of HIF-1αand downstream genes by a polyethyleneglycol- SN38 conjugate, EZN-2208, results in anti-angiogenic effects Angiogenesis 14 2011 245 253
27. E. Sasabe, X. Zhou, D. Li, N. Oku, and T. Yamamoto The involvement of hypoxia- inducible factor-1alpha in the susceptibility to gamma-rays and chemotherapeutic drugs of oral squamous cell carcinoma cells Int. J. Cancer 120 2007 268 277
28. G.L. Semenza Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy Trends Pharmacol. Sci. 33 2012 207 214
29. G.P. Spinelli, E. Miele, G. Lo Russo, M. Miscusi, and G. Codacci-Pisanelli Chemotherapy and target therapy in the management of adult high- grade gliomas Curr. Cancer Drug Targets 12 2012 1016 1031
30. S. Trabulo, A.M. Cardoso, T. Santos-Ferreira, A.L. Cardoso, and S. Simões Survivin silencing as a promising strategy to enhance the sensitivity of cancer cells to chemotherapeutic agents Mol. Pharm. 8 2011 1120 1131
31. Y.P. Tsai, and K.J. Wu Hypoxia-regulated target genes implicated in tumor metastasis J. Biomed. Sci. 19 2012 102
32. E.G. Van Meir, C.G. Hadjipanayis, A.D. Norden, and H.K. Shu Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma CA Cancer J. Clin. 60 2010 166 193
33. S.J. Veringa, D. Biesmans, D.G. van Vuurden, M.H. Jansen, and L.E. Wedekind In vitro drug response and efflux transporters associated with drug resistance in pediatric high grade glioma and diffuse intrinsic pontine glioma PLoS One 8 2013 e61512
34. X.L. Wang, R. Xu, X. Wu, D. Gillespie, R. Jensen, and Z.R. Lu Targeted systemic delivery of a therapeutic siRNA with a multifunctional carrier controls tumor proliferation in mice Mol. Pharm. 6 3 2009 738 746
35. M. Weller, R. Stupp, M. Hegi, and W. Wick Individualized targeted therapy for glioblastoma: fact or fiction? Cancer J. 18 2012 40 44
36. S. Yin, S. Kaluz, N.S. Devi, A.A. Jabbar, and R.G. de Noronha Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1αinteraction with cofactors p300/CBP Clin. Cancer Res. 18 2012 6623 6633
37. Q. Zhang, Z.F. Zhang, J.Y. Rao, J.D. Sato, J. Brown, D.V. Messadi, and A.D. Le Treatment with siRNA and antisense oligonucleotides targeted to HIF-1alpha induced apoptosis in human tongue squamous cell carcinomas Int. J. Cancer 111 6 2004 849 857